Affinity DataIC50: 0.200nMAssay Description:Inhibition of ET-1 binding to Endothelin A receptor in cultured rabbit renal artery vascular smooth muscle cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 0.470nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 0.650nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 0.820nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:Inhibition of ET-1 binding to Endothelin B receptor in cultured rat cerebellar membranesMore data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 2.60nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
Affinity DataIC50: 4.80nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Binding affinity against angiotensin II receptor type 1 (AT1) from rat liver.More data for this Ligand-Target Pair
Affinity DataIC50: 5.60nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 6nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 6.10nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
Affinity DataIC50: 7.40nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 7.40nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 7.5nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 7.60nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 8nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 8nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 9.10nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:In vitro binding affinity at angiotensin II (type 2) receptor in rabbit uterus.More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 12nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 12nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 14nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of ET-1 binding to Endothelin A receptor in cultured rabbit renal artery vascular smooth muscle cellsMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 15nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 15nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 17nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 17nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 18nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
Affinity DataIC50: 18nMAssay Description:In vitro binding affinity to the angiotensin II receptor, type 1 in rat liverMore data for this Ligand-Target Pair